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Abstract We propose a network model to identify the 
main drivers of consumer-based brand equity. We apply 
our research to assess the value of three over-the-counter 
drug brands. Our aim is to help manufacturers to 
improve their position in the market of self-medication. 
This market has very peculiar characteristics: consumers 
buy products in response to their specific health needs; 
nonetheless, the market is not strictly regulated in the 
same way that the prescription market, which allows 
firms to choose their pricing and communication 
strategies. Moreover, consumers are not forced by 
physicians to buy one specific drug, but they can choose 
the one they prefer. To develop our model we use the 
Analytic Network Process methodology, which allows 
integrating qualitative and quantitative judgments from 
many decision makers and deals with non-regular 
preference structures. The output of the model is a 
ranking of the brand value drivers, according to their 
importance in influencing the consumers’ purchase 
intentions. We find that advertising plays a major role in 
this setting. To test our model and validate our results, 
we analyse three Italian brands that produceover-the-
counter (OTC) Diclofenac-based drugs. In addition, we 
compare our results with their market share. 
 
Keywords Consumer-basedBrand Equity, Analytic 
Network Process, Brand Choice Behaviour, Intangible 
Assets, Over-the-counter Drugs 
                                         
1. Introduction 
 
In recent years the pharmaceutical industry experienced a 
decrease in its performance, which involved losses in 
profit margin and return on investments. This situation 
can be partially ascribed to the very peculiar nature of 
this industry: manufacturers face high costs for R&D 
activities and for patents, competition is high and the 
relationship with customers is often very constrained. In 
this context, reduced profit margin can impede – or, at 
least, make more difficult – the development of new 
products, which, for the most part, require long lead 
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times. Opportunities come from the attempt of 
governments to mitigate the costs of state-subsidized 
healthcare: these costs are already huge and are likely to 
grow with the shifting of age distribution toward an older 
population[1] In the last few years governments, have 
delisted many drugs, passing them from the prescription 
to the non-prescription market. The definition of “non-
prescription medicine” varies from country to country: in 
many cases, it is coincidental with “over-the-counter” 
(OTC) products, while in other cases, it is possible to 
further subdivide these products into other categories. In 
Italy, as an example, non-prescription drugs are 
subdivided in SOP (which in Italian stands for “without 
need of prescription”) and OTC: both include self-
medication drugs, but for the latter advertising is 
permitted – under the approval of the Italian Board of 
Health – whereas for the former it is not. Moreover, in the 
case of OTC drugs, manufacturers are also free to choose 
the price of their products. Under these specifications, it 
appears clear that OTC products can represent a 
potentially new source of value for the pharmaceutical 
industry: in fact, manufacturers are progressively less 
constrained in their relationship with consumers; 
specifically with regard to both pricing and 
communication strategies. Manufacturers can often 
leverage the reputation of the products they already 
produce, when launching new ones. In some cases, 
having a good reputation in the prescription medicines 
sector (Rx)helps to improve one’s position in the OTC 
market as well. 
 
Prior research has emphasized the strategic importance of 
brands in driving consumer choices. Brand image can 
make the difference in secure a sale when the consumer is 
uncertain and cannot choose among very similar 
products [2, 3]; it can also be a means to connect with 
consumers’ inner values [4] and to convey positive or 
negative feelings about product characteristics. Actually, 
it is often hard to assess a product’s full value before the 
purchase, especially when it has many complex features; 
so one has to rely on other users’ opinions or on the 
brand’s reputation. Accordingly, the quality of a product 
is often linked to its brand value [5]. Consistently, it is 
often the case that the perceived value of a product is 
highly influenced by more ethereal and less tangible 
elements. Furthermore, brand equity has proved to be 
positively related to market shares [6], purchase 
intensions and consumer preferences [7]. 
 
A large body of literature has studied ways to measure 
brand equity, and many different approaches can be 
identified: some adopting a financial perspective [8] – in 
order to determine the financial value of the brand; some 
focused on the strategic management of brands [9, 10]; 
others based on behavioural science and mainly focused 
on customer perceptions, taking into account the multiple 
dimensions of the brand value [11], analysing the 
concepts of brand strength and brand value [12], 
considering facets, such as perceived quality, perceived 
value for money, uniqueness, and the willingness to pay 
a price premium for a brand [13], or stressing the 
importance of brand knowledge and brand awareness 
[14]. Some private companies, such as Interbrand and the 
advertising agency Young & Rubicam, have also 
developed methodologies to asses brand value. 
 
In this paper, we try to identify the major drivers of 
brand value for OTC medicines, following a consumer-
based approach. Our research is intended to provide 
useful guidelines to the pharmaceutical companies who 
want to improve consumer awareness and the purchasing 
of self-medication drugs, when not strictly conditioned 
by a medical prescription. 
 
In a previous work we used a consumer-based approach 
to find the most important determinants of brand equity 
in the fashion industry [15]. By means of the Analytic 
Hierarchy Process (AHP), we found evidence to say that 
companies’ reputations and the strategies adopted to 
build consumer loyalty play a major role in determining 
the brand value as perceived by consumers; we also 
emphasized the importance of choosing the most 
appropriate price for products, having reliable after-sales 
services and paying attention to customer feedback. In 
the present study, we extend our previous research, using 
a more complete model to assess brand equity – we build 
our model under the general framework of the Analytic 
Network Process (ANP). The ANP is a more general 
approach to the theory of decision making than AHP. In 
the same way that AHP does, ANP allows integrating 
both qualitative and quantitative judgments from various 
decision makers, and to hypothesize a spreading of 
influence ofeach decisional element towards some others. 
Nonetheless, in the case of ANP the spreading of 
influence is not made to follow a top-down structure, 
rather it can follow any direction, thus building a 
network of influences. Alternative solutions to a stated 
problem can be considered as decisional elements and 
can receive/spread their influence from/towards other 
decisional criteria. In this way, non-regular structures of 
preferences can also be taken into account: as a person is 
aware of what the alternatives are, he/she can be willing 
to revise the importance assigned to each decisional 
element, thus showing a circular structure of preferences. 
 
As we move from the fashion industry [15] to the 
pharmaceutical industry, we need to reshape some of the 
brand equity determinants, to be more industry-specific. 
In fact, the former industry is characterized by products 
with less tangible features which can more easily connect 
with consumers’ inner feelings and desires. By contrast, 
products from the latter are often purchased by 
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The Analytic Network Process is a methodology 
developed by Thomas L. Saaty[16, 17], which is useful in 
dealing with complex problems and decisions that 
require multiple evaluation criteria and are characterized 
by bounded rationality. The ANP is a generalization of 
the Analytic Hierarchy Process: both methodologies are 
based on the consideration that solving a complex 
problem as a whole can be an issue that is too difficult to 
deal with. Therefore, the problem is treated as a system 
and is decomposed into less and less complex 
subsystems, so as to understand their operating 
principles. In doing so, however, it is important not to 
lose sight of the relations among the various parts that 
form the whole system. In the AHP these relations are 
accounted for by a hierarchical decomposition structure, 
whereas in the ANP they are represented by means of a 
network structure. In this latter representation, decisional 
elements are grouped together in clusters on the basis of 
their functional or structural homogeneity. The various 
decisional elements affect one another and they 
contribute to the solution of the main problem with a 
different degree of importance. So an element will be 
important if it assumes a priority over a great number of 
decisional variables. Therefore, the network of priorities 
has to be built and analysed. In this network, there is an 
arrow from a cluster Ci to a cluster Cj if some elements in 
Ci assume a priority over at least one element in Cj. 
Moreover, there is a loop on a component Ck, if some 
elements in Ck affect at least  one other element in Ck. 
When we deal with decisions, one of the clusters has to be 
dedicated to the alternative solutions; knowing which are 
the possible solutions to the problem, indeed, can affect 
the importance that the decision maker attributes to the 
various elements. 
 
Once the network of dependences has been built it is 
necessary to determine the impact of each decisional 
criterion over all the others, both on direct links and on 
paths of whichever length. To this end, the decision 
maker has to express an opinion on the importance of 
each element over the others to reach the goal, analyse 
the network structure and select the connected 
components. Given two connected components Ci and 
Cjan element in Cj is chosen as the control criterion and 
the elements in Ci are pairwise compared to determine 
which of them affect it the most. This step can be handled 
with an AHP logic: given the control criterion, a pairwise 
matrix is built in order to compare all the elements which 
affect the control criterion. For each couple of elements in 
the matrix the decision maker has to express a judgment 
on the relative importance in affecting the control 
criterion. In this step the decision maker can make use of 





1 Equal importance Two activities contribute equally to 
the objective 
2 Weak  
3 Moderate 
importance
Experience and judgment slightly 
favour one activity over another
4 Moderate plus  
5 Strong importance Experience and judgment strongly 
favour one activity over another
6 Strong plus  
7 Very strong or 
demonstrated 
importance 
An activity is favoured very 
strongly over another; its 
dominance is demonstrated in 
practice 
8 Very, very strong  
9 Extreme 
importance 
The evidence favouring one 
activity over another is of the 




If the activity i has 
one of the above 
nonzero numbers 
assigned to it 
when compared 
with activity j, 





Rationals Ratios arising 
from the scale 
If consistency is to be forced by 
obtaining n numerical values to 
span the matrix 
Table 1. Saaty’s AHP semantic scale Source: [18] 
 
If the judgments are consistent, the corresponding 
normalized principal eigenvector can be used to 
synthesize the local priorities of elements in Ci over the 
control criterion in Cj. 
 
Local priorities among decisional elements are summed-
up in a so-called supermatrixW, which has as many rows 
and columns as the number of decisional elements in the 
network. Decisional elements shown in this matrix are 
subdivided by components. Therefore, it is possible to 
find blocks in W, which correspond to the intersection 
between clusters Ci and Cj. If there is not a priority among 
the elements in Ci and the elements in Cj, the 
corresponding block of rows and columns in W will be 
identically null; otherwise, in the block between the two 
components we will find the local priorities of the 
elements in Ci over the elements in Cj, determined 
through the pairwise comparisons of the AHP 
methodology. 
 
It may happen that not all the components have the same 
importance in reaching the goal; therefore, the local 
priorities of the elements in Ci over the elements in Cj 
have to be weighted, considering the priority of Ci over 
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Cj. Weights can be determined through a control hierarchy, 
in which all the components of the ANP structure are 
pairwise compared by making use of the AHP. 
 
The combination of the priorities in the supermatrixW 
with the priorities among clusters gives a stochastic 
supermatrixWS, in which the generic element wlk 
represents the impact of the element el in Ci over the 
element ek in Cj, which is already weighted on the impact 
of the component Ci over Cj. The matrix WS can be 
considered as the adjacency matrix of a graph, in which 
arcs represent the priority network and their values 
impact between the two elements. Again, an element will 
be much more important for the decision making process 
if it impacts on a higher number of other decisional 
elements – impact, is measured not only on direct arcs, 
but also considering indirect influences over all the 
possible paths in the graph. Accordingly, these influences 
can be determined calculating WSk, with k→+∞, and are 
called Limiting Impact Priorities (LIP) of decisional 
elements; these priorities are defined between each pair 
of elements in the network. On the other hand, it is 
possible to determine a synthetic index for the priority of 
an element over the whole network: this index is called 
Limiting Absolute Priority (LAP) of the element; it can be 
proved that it is represented by the principal eigenvector 
of WSk. LIP and LAP depend on the characteristics of 
primitivity and reducibility of WS: if WS is imprimitive 
and irreducible then LIP does not exist. 
 
The ANP allows structuring complex models of influence 
spreading, which accounts for Benefits, Opportunities, 
Costs and Risks (B.O.C.R. models): a super-hierarchy has 
weights for the four macro-categories (B, O, C, and R) – or 
for a part of them; starting from each category, a network 
of influence among elements is developed. 
 
3. The B.O.R. model for OTC drugs consumer-based 
brand equity 
 
In order to develop a model to measure consumer-based 
brand equity for OTC drugs, we need to identify a set of 
determinants which can affect consumer choices. We started 
from the determinants of consumer-based brand equity 
defined in [15], adapting them to the present case study. 
 
First of all, we structured three macro-clusters for our 
model – including Benefits, Opportunities and Risks. It is 
worth nothing that our model does not include any 
determinant of the brand value pertaining to the cluster 
of Costs. This choice is mainly due to the peculiarities of 
the analysed scenario. To give an example, we can 
consider the price of the offered products and the time 
spent to reach the selling point: these two elements (costs) 
are pretty comparable for all the analysed drugs; 
accordingly they do not make a real difference in a 
consumer’s choice, so they were not included in the 
model. What is more important in this context is that the 
price of the product has to fit their quality and 
characteristics – and such a decisional element has been 
included in the Opportunities cluster. Then, we identified 
the decisional elements for each of the macro-categories 
and grouped them in clusters, consistently with the 
homogeneity conditions (the structure of the model is 
presented in Table 2). We were careful not to include 
more than nine elements in each cluster and no more than 
nine clusters in each network, so as to respect the 
principles of ANP/AHP methodology [18]. 
 
Network Cluster Criteria 













Emotional value of the 
brand 




Consumer base Capillarity and 
effectiveness of 
distribution






Ease in being recognized












ALL NETWORKS Alternatives Dicloreum 
Fastum 
Voltaren 
Table 2. Drivers of consumer-based brand equity for OTC drugs 
 
The main changes, compared to our previous work, 
concern the brand-equity determinants, which have to be 
revised on the basis of the specific nature of the products 
we are now considering. To give an example, the criterion 
“quality” presented in [15] can be translated as 
“effectiveness” in this study; “customization possibilities” 
is equivalent to “customization level”. Having also 
included the networks of opportunities and risks, “trend 
fitting” can be moved to the former network and grouped 
together with “pharmacist’s advice”; additionally, some 
other product characteristics can be considered as risks, 
such as the possibility of experiencing “side effects”. 
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ueness of the 
product
0.0938 0.0086











Media coverage 0.1935 0.0578
Emotional value 
of the brand 
0.0708 0.0212


















Market shares 0.2779 0.0350
Logo 
0.1332 
Drug naming 0.3914 0.0310
Logo design 0.2785 0.0221
Logo uniqueness 0.1519 0.0121































Table 4. Local and global priorities of decisional elements in the 
B.O.R. model 
 
Local and global priorities for the identified drivers of 
brand equity are shown in Table 4. Table5 shows the 









• WA is the global weight of alternative A in the B.O.R. 
model; 
• WAB, WAO and WAR are the local weights of 
alternative A in the three networks ofbenefits, 
opportunities and risks; 
• b, o, and r are the weights of benefits, opportunities 
and risks with respect to the goal of assessing brand 
value. 
 















Table 5. Overall outcome for alternatives 
 
As can be noted, the main category is that of benefits, 
which accounts for roughly 60% of brand value. In this 
category, the main drivers are “advertising 
expenditures”, “presence in international markets” and 
“media coverage”, which,when combined, amount to 
almost 25% of global priority, corresponding to more 
than 40% in the benefit category. In the “opportunity” 
category, the three criteria have roughly the same 
importance, with a slight preference on “appropriate 
pricing strategy”. Finally, looking at risks, the main 
driver is the availability of “substitute products”, 
whereas “side effects” accounts for 10.66% of global 
priority, corresponding to 46% in the risk category. 
 
The overall outcomes for the alternatives show that – 
balancing benefits, opportunities and risks – the preferred 
OTC drug is Voltaren (79%), followed by Fastum (14%) 
and Dicloreum (7%). 
 
This ranking among drugs is consistent with the one 
presented by the Italian Board of Health, which shows 
the list of the 50 OTC drugs supplied to most drugstores 
and authorized shops in the first half of 20121: Dicloreum 
does not appear in this list, therefore, it is not among the 
first 50 drugs. 
 
Participating drugstores 
 Voltaren Fastum Dicloreum Lasonil Momentdol
Before 
event
69.96% 10.45% 8.76% 7.77% 3.07%
After 
event
66.81% 16.36% 6.88% 7.13% 2.82%
Non-participating drugstores 
 Voltaren Fastum Dicloreum Lasonil Momentdol
Before 
event
69.33% 9.91% 8.29% 9.26% 3.20%
After 
event
68.44% 12.34% 6.75% 9.25% 3.23%
Table 6. Market shares of Diclofenac-based drugs (Source: 
Federfarmaco2) 
                                                                 
1 http://www.salute.gov.it/imgs/C_17_pubblicazioni_1817_allega 
to.pdf 
Int J Eng Bus Manag, 2014, 6:20 | doi: 10.5772/591576 www.intechopen.com
Our results can also be compared with a report2 made by 
Federfarmaco Ltd., which is an association of 26 
cooperatives of drugstores, with a total of 11,400 stores all 
over Italy (together they represent 35% of business 
volume for the intermediate supply of medicines). This 
report compares the market shares of five Diclofenac-
based drugs – including Dicloreum, Fastum and Voltaren 
– before and after a suggested price cut for Fastum 
products in some drugstores. 329 drugstores took part to 
this event and 99 of them put the suggested price cut into 
effect. The event took place in April 2013 and 
Federfarmaco monitored the market shares, both in 
participating and non-participating drugstores (the 
results are presented in Table 6). 
 
If we normalize market shares considering only the first 
three players, we obtain the values in Table 7; this table 
also shows the compatibility index (SI) values resulting 
from the comparison with final scores from our model: this 
index allows the comparing of two vectors of priorities and 









9.82% 11.72% 78.46% 1.0329
After 
event 






9.47% 11.32% 79.21% 1.0318
After 
event 
7.71% 14.10% 78.19% 1.0003
Table 7. SI index for normalized market shares of diclofenac-
based drugs 
 
Our results are significantly similar to the rankings 
presented in Table 7. Consistently, we find more evidence 
to support our model. 
 
To extend the comparison between our results and the 
market shares at a national level we once more consider 
the list of the Italian Board of Health1. This list also shows 
the number of packages supplied for each drug (Table8). 
As Dicloreum is not in the list, we assume for it to have 
the same quantity as for the 50th drug (Zerinol). This is the 
best possible situation for Dicloreum. 
 
Drug Position 




number of units 
supplied 
Dicloreum >50 525,395 14.49%
Fastum 41 598,346 16.50%
Voltaren 3 2,501,975 69.01%
Table 8. Quantity supplied to drugstores and authorized shops 
for the three OTC drugs in the first half of 2012 (Source: Italian 
Board of Health1) 
                                                                 
2 http://www.federfarmaco.it/nl/repository//RISULTATI%20EVE 
NTO%20FASTUM.pdf 
The comparison between our results and the official data 
of the Board of Health provides a value for SI of 1.1118, 
higher than the admissible upper bound – equal to 1.100 – 
set by Saaty for the compatibility index (see [19]). We are 
exceeding this limit of 1.18%. This result can be due to a 
higher hypothesized provided quantity for Dicloreum 
than the actual one. 
 
If we hypothesize a lower value for the provided 
quantities of Dicloreum SI improves: in particular, SI 
reaches its admissible upper bound for a provided 
quantity of 504,856 units, which corresponds to a 
decrease of 3.91% in the hypothesized quantity. If this is 
the case, the new vector of actual priorities for our OTC 
drugs would be that shown in Table 9. It is worth noting 
that the variation in actual priorities of Fastum and 
Voltaren is lower than 1%, while that of Dicloreum is 
slightly over 3%. Therefore, a little error in estimating the 
correct value for Dicloreum provisions can be the cause of 
our exceeding SI: a little adjustment would be required in 




















Dicloreum >50 504,856 14.00% -3.36%
Fastum 41 598,346 16.60% +0.57%
Voltaren 3 2,501,975 69.40% +0.57%
Table 9. Vector of hypothesized priorities which returns an 
acceptable SI 
 
Provisions of Dicloreum should not fall below 152,150 
units, a value which determines SI to rise again to its 
acceptable upper bound. Therefore, all provisions of 
Dicloreum in [152,150; 504,856] – which corresponds to an 
interval [4.68%; 14.00%] for Dicloreum share in the set of 
our three OTC – gives an acceptable SI value. This is 
likely to happen, as the report by Federfarmaco shows. 
 
6. Discussion and conclusions 
 
We propose an ANP model to identify and assess the major 
drivers of consumer-based brand equity for OTC drugs in 
the Italian self-medication market. In 2012, these medicines 
represented 72.3%, in terms of volume, of the non-
prescription market, which in turn amounted to 13.3% of the 
whole medication market [20]. OTC drugs can be an 
important source of value for drug manufacturers, as prices 
are not constrained by law and product characteristics can 
be promoted via advertising (under the approval of the 
Italian Board of Health). Moreover, self-medication 
consumers’ behaviour is not imposed by physicians 
through prescription: consumers are free to choose 
whatever drug they like to fulfil their health needs. Brand 
value, therefore, emerges as a valuable asset for medicine 
manufacturers and has to be effectively managed. 
Elisa Battistoni, Andrea Fronzetti Colladon and Paolo Puglia: Exploiting the Potential Value of 
Over-the-counter Drugs Through Brand Equity: An Analytic Network Process Approach
7www.intechopen.com
In our model, we hypothesize three macro-categories of 
drivers (Benefits, Opportunities and Risks), each made of 
different clusters, influencing consumer choices. The 
results show a sharp priority of benefits, which account 
for almost 60% in determining consumer behaviour. 
Among the benefits, the highest importance is given to 
“communication strategies”, followed by “consumer 
base”. Among the drivers of communication strategies 
the highest priority is assigned to “advertising 
expenditures” (20.74% among benefits), followed by 
“media coverage” (9.71%), “use of popular testimonials” 
(8.83%) and “corporate social responsibility initiatives” 
(7.32%). These four out of five drivers of communication 
strategies occupy the first four positions in the priority 
ranking of benefits. “Communication strategy” cluster 
has roughly 50% of priority. 
 
Generally speaking, one may think that, investing in 
advertising for OTC drugs is not beneficial to their 
consumption [20]: in fact, consumers choose to acquire 
self-medication drugs only if needed, given the peculiar 
nature of these products. By contrast, our analysis points 
out that “communication strategies” play a major role in 
guiding consumer behaviour. This is probably due to the 
existence of more than one OTC drug, which can compete 
to fulfil a specific health need. Accordingly, the consumer 
has the duty of choosing among different products. In this 
setting, advertising can guide a consumer’s choice toward 
the selection of one specific brand over the competing 
alternatives. This is also supported by the results for drivers 
of risks, where the main reason not to choose a specific drug 
is set on “availability of substitute products”, which has a 
higher priority than the risk of incurring in “side effects”. 
Moreover, the opportunity network results support the 
previous considerations: in fact, the first driver appears to be 
the setting of an “appropriate pricing strategy”, followed by 
“pharmacists’ advice”: both these criteria can be thought of 
as indirect communication elements, even if they have 
different nature and characteristics. 
 
It is interesting to notice that, among benefits, the first 
eight positions are not occupied by any of the product 
characteristics, which account for only 15% of benefits. 
This is mainly because our study considered products 
with the same active ingredient that are also sufficiently 
homogeneous in their effects. Finally, the last positions in 
the ranking of benefit drivers are dedicated to three out of 
four elements in the “logo” cluster, which only accounts 
for 13% of benefit priorities. 
 
In the practice of management, organizational and less 
tangible factors often play a role that is stronger or 
equivalent to technical ones [21]. In a very peculiar 
industry, such as the pharmaceutical one, it will be useful 
to cross-subsidize R&D and new product development 
activities, to invest in these activities and to recognize the 
importance of intangible assets, which is vital to maintain 
a competitive advantage [22]. Accordingly, we suggest 
integrating a deep understanding of customer needs, 
values and perceptions within the knowledge 
management practices. Indeed, the pharmaceutical 
industry is a knowledge-intensive industry: for firms 
operating in such an industry to overcome their 
competitors Zack suggests a knowledge strategy made up 
by the combination of exploitation of existing knowledge 
and the exploration of new knowledge [23]. In fact, 
according to Zack “exploration provides the knowledge 
capital to propel the company into new niches while 
maintaining the viability of existing ones. Exploitation of 
that knowledge provides the financial capital to fuel 
successive rounds of innovation and exploration. 
Exploration without exploitation cannot be economically 
sustained over the long run unless it is subsidized or 
directly generating a revenue stream (e.g., a research 
institute). Exploitation without exploration will 
ultimately result in trying to pump from a dry well.” 
 
To conclude, we maintain that our model can help 
manufacturers in addressing the most effective drivers to 
improve their presence in the market and to exploit the 
potential value of their non-prescription drugs – 
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